ImmunityBio (IBRX) Operating Margin (2014 - 2026)
ImmunityBio's (IBRX) quarterly Operating Margin came in at 157.88% in Q1 2026, up 23220.0% year-on-year from N/an in Q1 2025, and up 6.55% on a QoQ basis from 168.95% in Q4 2025.
ImmunityBio (IBRX) Operating Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Operating Margin data on file, last reported at 157.88% in Q1 2026.
- On a quarterly basis, Operating Margin rose 23220.0% year-over-year to 157.88% in Q1 2026; TTM through Mar 2026 was 185.41%, a 81841.0% increase from a year earlier, with the FY2025 full-year figure at 226.0%, up 210823.0% from the prior year.
- Operating Margin for Q1 2026 stood at 157.88%, up from 168.95% in the prior quarter.
- Over the last five years, Operating Margin for IBRX reached as high as 157.88% in Q1 2026 and fell as low as 685514.29% in Q1 2022.
- Historically, Operating Margin has averaged 103232.55% across 5 years, with a median of 30994.44% in 2023.
- Across the five-year window, Operating Margin plunged 62345385 bps in 2022 and jumped 65451984 bps in 2023, its largest moves.
- Year by year, Operating Margin stood at 116301.37% in 2022, then soared by 47 bps to 61430.94% in 2023, then surged by 99 bps to 918.96% in 2024, then soared by 82 bps to 168.95% in 2025, then gained by 7 bps to 157.88% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 157.88% in Q1 2026, 168.95% in Q4 2025, and 173.51% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ImmunityBio | 7.60 Bn | 7.22 Bn | 43.97 Mn | -157.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.88% |
| Dec 31, 2025 | -168.95% |
| Sep 30, 2025 | -173.51% |
| Jun 30, 2025 | -269.76% |
| Mar 31, 2025 | -390.08% |
| Dec 31, 2024 | -918.96% |
| Sep 30, 2024 | -1,314.33% |
| Jun 30, 2024 | -9,487.39% |
| Mar 31, 2024 | -237,990.00% |
| Dec 31, 2023 | -61,430.94% |
| Sep 30, 2023 | -97,726.83% |
| Jun 30, 2023 | -207,670.73% |
| Mar 31, 2023 | -30,994.44% |
| Dec 31, 2022 | -116,301.37% |
| Sep 30, 2022 | -76,952.54% |
| Jun 30, 2022 | -227,491.43% |
| Mar 31, 2022 | -685,514.29% |
| Dec 31, 2021 | -20,326.67% |
| Sep 30, 2021 | -119,448.48% |
| Jun 30, 2021 | -25,341.00% |